This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerson, S. L.
Right arrow Articles by Kuter, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerson, S. L.
Right arrow Articles by Kuter, D. J.

 Previous Article

Antimicrobial Agents and Chemotherapy, August 2002, p. 2723-2726, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2723-2726.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Hematologic Effects of Linezolid: Summary of Clinical Experience

Stanton L. Gerson,1* Sheldon L. Kaplan,2 Jon B. Bruss,3 Vu Le,3 Felix M. Arellano,4 Barry Hafkin,4 and David J. Kuter5

Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University & University Hospitals of Cleveland, Cleveland, Ohio,1 Department of Pediatrics, Baylor College of Medicine, Houston, Texas,2 Pharmacia, Kalamazoo, Michigan,3 Pharmacia, Peapack, New Jersey,4 Hematology/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts5

Received 29 August 2001/ Returned for modification 14 December 2001/ Accepted 2 May 2002

Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at >=2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.

* Corresponding author. Mailing address: Division of Hematology/Oncology and Ireland Cancer Center, BRB 3, Case Western Reserve University & University Hospitals of Cleveland, 10900 Euclid Ave., Cleveland, OH 44106-4937. Phone: (216) 368-1176. Fax: (216) 368-1166. E-mail: slg5{at}cwru.edu.

Antimicrobial Agents and Chemotherapy, August 2002, p. 2723-2726, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2723-2726.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mave, V., Garcia-Diaz, J., Islam, T., Hasbun, R. (2009). Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?. J Antimicrob Chemother 64: 175-180 [Abstract] [Full Text]  
  • Grim, S. A., Rene, L., Gupta, S., Clark, N. M. (2008). Safety of linezolid in patients with baseline thrombocytopenia. J Antimicrob Chemother 62: 850-851 [Full Text]  
  • Kohno, S., Yamaguchi, K., Aikawa, N., Sumiyama, Y., Odagiri, S., Aoki, N., Niki, Y., Watanabe, S., Furue, M., Ito, T., Croos-Dabrera, R., Tack, K. J. (2007). Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 60: 1361-1369 [Abstract] [Full Text]  
  • de Jesus Valle, M. J., Uranga, N. S., Lopez, F. G., Hurle, A. D.-G., Navarro, A. S. (2007). Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery. J Antimicrob Chemother 60: 1074-1079 [Abstract] [Full Text]  
  • Soriano, A., Ortega, M., Garcia, S., Penarroja, G., Bove, A., Marcos, M., Martinez, J. C., Martinez, J. A., Mensa, J. (2007). Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid. Antimicrob. Agents Chemother. 51: 2559-2563 [Abstract] [Full Text]  
  • Mortin, L. I., Li, T., Van Praagh, A. D. G., Zhang, S., Zhang, X.-X., Alder, J. D. (2007). Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria. Antimicrob. Agents Chemother. 51: 1787-1794 [Abstract] [Full Text]  
  • Maclayton, D. O, Hall II, R. G (2007). Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. The Annals of Pharmacotherapy 41: 235-244 [Abstract] [Full Text]  
  • McKee, E. E., Ferguson, M., Bentley, A. T., Marks, T. A. (2006). Inhibition of Mammalian mitochondrial protein synthesis by oxazolidinones.. Antimicrob. Agents Chemother. 50: 2042-2049 [Abstract] [Full Text]  
  • Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., Warren, R. E., on behalf of the Joint Working Party of the Britis, (2006). Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 57: 589-608 [Abstract] [Full Text]  
  • Grau, S., Morales-Molina, J. A., Mateu-de Antonio, J., Marin-Casino, M., Alvarez-Lerma, F. (2005). Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 56: 440-441 [Full Text]  
  • Meyer, B., Kornek, G. V., Nikfardjam, M., Karth, G. D., Heinz, G., Locker, G. J., Jaeger, W., Thalhammer, F. (2005). Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 56: 172-179 [Abstract] [Full Text]  
  • Fortun, J., Martin-Davila, P., Navas, E., Perez-Elias, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gomez-Mampaso, E., Moreno, S. (2005). Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56: 180-185 [Abstract] [Full Text]  
  • Weigelt, J., Itani, K., Stevens, D., Lau, W., Dryden, M., Knirsch, C., the Linezolid CSSTI Study Group, (2005). Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue Infections. Antimicrob. Agents Chemother. 49: 2260-2266 [Abstract] [Full Text]  
  • De Bels, D., Garcia-Filoso, A., Jeanmaire, M., Preseau, T., Miendje, Y., Devriendt, J. (2005). Successful treatment with linezolid of septic shock secondary to methicillin-resistant Staphylococcus aureus arthritis. J Antimicrob Chemother 55: 812-813 [Full Text]  
  • Bassetti, M., Vitale, F., Melica, G., Righi, E., Di Biagio, A., Molfetta, L., Pipino, F., Cruciani, M., Bassetti, D. (2005). Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 55: 387-390 [Abstract] [Full Text]  
  • Senneville, E., Legout, L., Valette, M., Yazdanpanah, Y., Giraud, F., Beltrand, E., Obert, G., Dubreuil, L., Migaud, H., Mouton, Y. (2004). Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother 54: 798-802 [Abstract] [Full Text]  
  • Razonable, R. R., Osmon, D. R., Steckelberg, J. M. (2004). Linezolid Therapy for Orthopedic Infections. Mayo Clin Proc. 79: 1137-1144 [Abstract]  
  • Rho, J. P., Sia, I. G., Crum, B. A., Dekutoski, M. B., Trousdale, R. T. (2004). Linezolid-Associated Peripheral Neuropathy. Mayo Clin Proc. 79: 927-930 [Abstract]  
  • Raad, I., Hachem, R., Hanna, H., Afif, C., Escalante, C., Kantarjian, H., Rolston, K. (2004). Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 53: 646-649 [Abstract] [Full Text]  
  • Wilcox, M., Nathwani, D., Dryden, M. (2004). Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 53: 335-344 [Abstract] [Full Text]  
  • Chiang, F.-Y., Climo, M. (2003). Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 3002-3004 [Abstract] [Full Text]  
  • Rubinstein, E., Isturiz, R., Standiford, H. C., Smith, L. G., Oliphant, T. H., Cammarata, S., Hafkin, B., Le, V., Remington, J. (2003). Worldwide Assessment of Linezolid's Clinical Safety and Tolerability: Comparator-Controlled Phase III Studies. Antimicrob. Agents Chemother. 47: 1824-1831 [Abstract] [Full Text]  
  • Smith, P. F., Birmingham, M. C., Noskin, G. A., Meagher, A. K., Forrest, A., Rayner, C. R., Schentag, J. J. (2003). Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 14: 795-801 [Abstract] [Full Text]  
  • Stalker, D. J., Jungbluth, G. L., Hopkins, N. K., Batts, D. H. (2003). Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51: 1239-1246 [Abstract] [Full Text]  
  • (2002). Hematologic Effects of Linezolid. JWatch Infect. Diseases 2002: 3-3 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»